Secura Bio, Inc.

ACTIVE

1995 Village Center Cir Ste 128, Las Vegas, Nevada, United Statessecurabio.comHolding11–50 employeesEstablished: 2019-01-01

Clinical Trials

5 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2019

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

71.4%

Phase 2

28.6%

Trial Status Distribution

Active, not recruiting

71.4%

Completed

28.6%

Clinical Trials

Trials sponsored by this organization (7)

A Study of Duvelisib in Patients with Relapsed or Refractory Peripheral T cell Lymphoma (PTCL)

Phase 2

Completed

interventional

Jan 2020120 participants

Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myeloma

Phase 1

Active, not recruiting

Oct 2016240 participants

Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myeloma

Phase 1

Active, not recruiting

Jun 2016240 participants

Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myeloma

Phase 1

Active, not recruiting

May 2016240 participants

Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myeloma

Phase 1

Active, not recruiting

May 2016240 participants

Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myeloma

Phase 1

Active, not recruiting

Mar 2016240 participants

A Study of Duvelisib in Patients with Relapsed or Refractory Peripheral T cell Lymphoma (PTCL)

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

Approvals

FDA

Food and Drug Administration

Approvals

Recent Approvals

News

No news articles found

Back to Organizations